Leading clinical immunology into its next chapter.

HI-Bio™ leverages human genetic and immunological insights to deliver targeted therapies to patients with severe immune-mediated diseases (IMDs). With clinical-stage programs and pipeline, HI-Bio has the potential to address diseases across the immune landscape.

Press Release

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

View More

Who We Are

Our team’s track record developing and commercializing therapies powers our work at the forefront of precision medicine.

Join the Team

Driven to make an impact on the lives of patients with severe immune-mediated diseases? Excited to work as part of a collaborative team? Say ‘HI’ and let us get to know each other.

Contact Us